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Genetically modiﬁed miceMitogen-activated protein kinases (MAPKs) are involved in the regulation of cardiac hypertrophy and myocyte
survival. Extracellular signal regulated protein kinase 1 and 2 (ERK1/2) are key components in the MAPK
signaling pathways. Dysfunction of ERK1/2 in congenital heart diseases (Noonan syndrome and LEOPARD
syndrome) leads to cardiac hypertrophy. ERK2 contributes 70% of protein content to total ERK1/2 content in
myocardium; however, the speciﬁc role of ERK2 in regulating cardiac hypertrophy is yet to be further deﬁned.
To investigate the speciﬁc role of ERK2 played in the cardiomyocytes, we generated and examined mice
with cardiomyocyte-speciﬁc deletion of the erk2 gene (ERK2cko mice). Following short-term pathological
hypertrophic stresses, the mutant mice showed attenuated hypertrophic remodeling characterized by a blunted
increase in the cross-sectional area of individual myocytes, downregulation of hypertrophic foetal gene markers
(ANP and BNP), and less interstitial ﬁbrosis. However, increased cardiomyocyte apoptosis was observed. Upon
prolonged stimulation, ERK2cko mice developed deterioration in cardiac function. However, absence of ERK2
did not affect physiological hypertrophy induced by 4 weeks of swimming exercise.
These results revealed an essential role for ERK2 in cardiomyocytes in the development of pathological hyper-
trophic remodeling and resistance to cell death.
Crown Copyright © 2014 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Human pathological cardiac hypertrophy is not only a risk factor for
heart failure and suddendeath [1], but also a common cause ofmortality
and morbidity in congenital heart diseases (CHDs) [2]. Noonan
syndrome (NS) and LEOPARD syndrome (LS), termed as RASopathies,
are two autosomal dominant disorders with congenital manifestation
of heart defects. Clinical assessments showed that NS patients exhibit
pulmonary valve stenosis accompanied with cardiac malformations;
the dominant cardiac defect in 90% of LS cases is hypertrophic
cardiomyopathy [3,4]. Genetic studies revealed that these syndromes
are both, at least in part, related to themutation of non-receptor proteinSciences, the University of
hester M13 9PT, UK. Tel.: +44
r Ltd. This is an open access article utyrosine phosphatase type 11 (PTPN11) gene which encodes the SH2
containing protein tyrosine phosphatase (SHP2) [3–5]. The mutants
showed dysfunction of the Ras-Raf-ERK1/2 signaling pathway. NS
associated mutation potentiated Ras-ERK1/2 activation [6,7]. In
addition, gain-of-function studies of SHP2 exhibited the NS-like
syndrome accompanied by enhanced activation of ERK1/2 in the heart
[8,9]. By contrast, LS mutants behaved as loss-of-function mutations of
SHP2, impairing ERK activation [10–12].
Within the heart, ERK1/2 are activated at the plasma membrane by
Raf-1, followed by activation of small G protein Ras [13]. Harris et al.
showed that dominant negative Raf-1 inhibited ERK1/2 activation
in transgenic mice, which were resistant to hypertrophic stress but
developed signiﬁcant cardiomyocyte apoptosis [14]. Although cardiac-
speciﬁc Raf-1 knockout mice demonstrated heart dysfunction in the
absence of cardiac hypertrophy, associated with more apoptotic
cardiomyocytes through a MEK/ERK independent mechanism [15],
recent studies have suggested that ERK1/2 appear to be an essential
cardiac protector during stress stimulation [16–19].
ERK1/2 have been implicated as the regulators of cardiac hypertro-
phy in both cell culture and genetically modiﬁed mouse models. Fornder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
105S. Ulm et al. / Journal of Molecular and Cellular Cardiology 72 (2014) 104–116example, in cultured cardiomyocytes, it is suggested that ERK1/2 activa-
tion promotes hypertrophic growth [20]. Transgenic mice overexpress-
ing MEK1 had robust cardiac hypertrophy associated with activation of
ERK1/2 [18]. Nevertheless, dual-speciﬁcity phosphatase 6 (DUSP6)
knockout mice with spontaneously increased ERK1/2 phosphorylation
induced larger hearts due to hypercellularity of myocytes compared to
wild type mice [19]. However, complete inhibition of ERK1/2 activity
by DUSP6 overexpression in transgenic mice or loss expression of
ERK1/2 in the ERK1 null cross mated ERK2 cardiomyocyte-speciﬁc
deletion mice did not reduce cardiac hypertrophy following differentERK2f/f  E
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Fig. 1. Characterisation of cardiomyocyte-speciﬁc deletion of ERK2. (A) Quantitative real-time P
and liver. A 73% decrease inmRNA level was shown only in LV of ERK2cko mice in comparison to
and normalized to GAPDH content (n= 3). (B) Immunoblot analysis conﬁrmed speciﬁcity of
served as protein loading control. The ratio of ERK2 expression to tubulin is shown in the bar gr
of ERK1 and MEK1/2. Expression of ERK3, ERK4, ERK5, p38 and JNK in ventricular extracts wa
activity was examined on the tissue subjected to 1 week of TAC, demonstrating ERK1 activatio
Data presented as mean ± SEM.pathological stimuli [21]. The biological role of ERK1/2 in heart hyper-
trophy is conﬂicting; thus, the understanding of regulation by ERK1/2
in the heart remains elusive.
Global gene target studies showed that ERK1 deﬁcient knockout
mice are fertile, viable and of normal size [22]. In contrast, ERK2 knock-
outmice die during embryogenesis at day 11.5 due to an abnormality of
placental development causing secondary effects such as a thin heart
wall and growth retardation [23], which indicates that they may play
different roles in vivo. ERK2 contributes 70% of protein content to total
ERK1/2 content in myocardium [17]. Therefore, the unique regulationRK2cko ERK2f/f  ERK2cko ERK2f/f  ERK2cko
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ERK2 deletion in LV. ERK2 protein expression was comparable in various tissues. Tubulin
aph. (C) Western blot analyses demonstrated unchanged activation and expression levels
s the same in all genotypes. Tubulin served as protein loading control. (D) ERK1/2 kinase
n did not compensate the loss of ERK2 in the heart (n= 5). n.s.: no signiﬁcant difference.
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mine the in vivo role of ERK2 in the heart, we generated cardiomyocyte-
speciﬁc ERK2 deleted mice (ERK2cko). The deletion of ERK2 in
cardiomyocytes alone did not affect heart development and was not
compensated by ERK1. Thereafter, ERK2cko mice were exposed to pres-
sure overload or β-adrenergic stimulation for various time points; the
absence of ERK2 resulted in blunted hypertrophic growth and increased
susceptibility to heart failure due to apoptosis. Conversely, ERK2 wasCa
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Fig. 2. Attenuated hypertrophic response in ERK2cko mice following short-term TAC. (A) HW
(B) ERK2cko mice developed less hypertrophy after 1 or 2 weeks of TAC. Haematoxylin/eosin
mean cross-sectional area showed less enlarged ERK2cko cardiomyocytes (lower panel). (C) M
in ERK2cko-TAChearts (scale=50 μm). Quantiﬁcation of the relative area ofﬁbrosis is expressed
the number of apoptotic nuclei in ERK2cko ventricles compared to that in ERK2f/f ventricles afte
(dPW) and fractional shortening (FS%) were shown to demonstrate cardiac function. n= 7. #not involved in the regulation of physiological hypertrophy induced by
long-term swimming exercise.
2. Materials and methods
All mice used in this studyweremaintained in a pathogen-free facil-
ity at the University of Manchester. The animal studies performedwere
in accordance with the UK Home Ofﬁce and institutional guidelines. An-TAC
f/f   ERK2cko ERK2f/f   ERK2cko
TAC 2w-TAC
2w-TAC
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<0.01
p<0.01
p<0.05<0.01
/TL ratios of ERK2f/f and ERK2cko mice were calculated following sham or TAC treatment.
staining of ventricular cross-sections (top panel, scale = 20 μm). The measurement of
asson's trichrome staining of the hearts demonstrated less interstitial ventricular ﬁbrosis
as a percentage of theﬁbrosis area in themicroscope view. (D) The bar graph summarizes
r 1w- or 2w-TAC. (E) Parameters of end-diastolic left ventricular posterior wall thickness
or *, P b 0.05 ERK2cko versus ERK2f/f. Data presented as mean ± SEM.
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Fig. 2 (continued).
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2.1. Generation of ERK2 cardiomyocyte-speciﬁc knockout mice
Mice with modiﬁcation in the erk2 gene with LoxP elements
ﬂanking exon 2 and 3 (ERK2f/f) [24] were cross mated with mice
expressing Cre under a myosin light chain (MLC2v) promoter to
generate cardiomyocyte-speciﬁc ERK2 knockout mice (ERK2cko).
2.2. Hypertrophic models
Cardiac hypertrophy was induced by transverse aortic constriction
(TAC) or a sham operation under anaesthesia with a mixture of keta-
mine (100 mg/kg) and xylazine (5 mg/kg), 0.1 mg/kg buprenorphine
and artiﬁcial ventilation on 8 week old male ERK2cko mice and the
control littermates ERK2f/f mice, or by administration of isoproterenol
(ISO, Sigma-Aldrich) at 10 mg/kg/day via osmotic mini-pumps (Alzet)implantation as previously described [25,26]. ERK2f/f and ERK2cko mice
were also subjected to a 4-week swimming exercise to induce physio-
logical cardiac hypertrophy as previously described [25].
2.3. Echocardiography
Mice were anesthetized with Avertin (200 mg/kg). To evaluate
the cardiac function, transthoracic 2D M-mode echocardiographic
recordings were performed using an Acuson Sequoia C256 ultra-
sound system (Siemens) following a protocol described previously
[25,26].
2.4. Histology analyses and terminal deoxynucleotidyl transferase dUTP
nick end labelling (TUNEL) assay
5 μm thick parafﬁn sectionswere cut and stainedwith haematoxylin
& eosin to measure cardiomyocyte cross-sectional areas, and stained
using the Masson's trichrome method to examine interstitial ﬁbrosis
108 S. Ulm et al. / Journal of Molecular and Cellular Cardiology 72 (2014) 104–116as described [25,26]. TUNEL assay was performed to detect apoptosis
using the in situ Cell Death Detection kit (Roche).
2.5. Immunoblot analyses
Protein extracts (30 μg) were subjected to Western blot analyses
with the primary antibodies against ERK1 (Santa Cruz), ERK2 (Santa
Cruz), ERK5 (Upstate), Phospho-ERK5 (Invitrogen), p38 (Santa Cruz),
Phospho-ERK1/2, MEK1/2, Phospho-MEK1/2, Phospho-p38, JNK1/2,
Phospho-JNK1/2, PKB, Phospho-PKB, active caspase 3 (Cell signaling)
orα-Tubulin (Sigma-Aldrich). Immunecomplexeswere detected by en-
hanced chemiluminescence with anti-mouse, anti-rabbit or anti-goat
immunoglobulin G-coupled to horseradish peroxidase as the secondary
antibody (Amersham-Pharmacia).
2.6. ERK1/2 kinase assay
Tissue samples were homogenized in triton lysis buffer (Supple-
mentary materials and methods). Protein extracts were applied
for ERK1/2 kinase assay following the manufacturer's instruction
(Cell Signaling).
2.7. siRNA transfection of neonatal rat cardiomyocytes (NRCMs)
NRCMs were prepared as previously described [24–26]. NRCMs
were transfected with either control siRNA (Sigma-Aldrich) or ratANP
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Fig. 3.Quantitative real-time PCR analyses of hypertrophic genemarkers and ﬁbrosis genemark
performed in triplicate and normalized to GAPDH content (n= 3). Data presented as mean ±ERK2 siRNA (gene ID #116590; si genome SMART pool, Dharmacon)
using Lipofectamine Plus reagent according to the manufacturer's in-
struction (Invitrogen) for 48 h prior to phenylephrine (PE, 30 mM,
Sigma-Aldrich) treatments or 100 μM H2O2 treatments.
2.8. Immunocytochemistry
NRCMs on laminin-coated coverslips were transfected with control
or ERK2 siRNA, followed by treatmentwith PE for 48 h. Thereafter, triple
immunostaining was performed using anti-ANP antibody (Peninsula
Laboratories) and anti-α-actinin antibody (Sigma-Aldrich) accompa-
nied by nuclei detection by 4′,6-diamidino-2-phenylindole (DAPI,
Invitrogen).
2.9. Luciferase reporter assay
NRCMs transfected with either control siRNA or ERK2 siRNA were
infected with virus encoding brain natriuretic peptide (BNP) Ad-BNP-
Luc at 25 MOI for 24 h followed by 24 hour treatment of PE (30 μM).
BNP reporter activity was analysed using luciferase assay kit (Promega).
2.10. Quantitative real-time PCR
Real time quantitative PCRs were performed using SYBR Green PCR
Master Mix (Applied Biosystems) according to the manufacturer's rec-
ommendations. Primers to identify ERK2, ANP, BNP, Collα2, Col3α1,BNP
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Fig. 4. Analysis of hypertrophic regulators in ERK2f/f and ERK2cko ventricles. Protein
extracts from ERK2f/f and ERK2cko ventricles after 1 week of sham or TAC operation
were subjected to immunoblot analyses for total ERK2, ERK1, MEK1/2, PKB, p38, JNK
and ERK5 expression as well as their phosphorylation levels using speciﬁc antibodies.
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formed in the 7500 Real Time PCR System (Applied Biosystems), and
the results were analysed using the 2-ΔΔCT method [27].
2.11. Statistical analysis
Data were expressed as means ± SEM and statistical comparisons
between groups were analysed using the paired Student's t test; for
multiple comparisons 1- or 2-way ANOVA followed by Bonferroni
post-hoc was used where appropriate. A value of p b 0.05 was consid-
ered to be statistically signiﬁcant between groups.
3. Results
3.1. Characterization of ERK2cko mice
Due to the embryonic lethality caused by conventional gene
targeting of the erk2 gene, we generated mice with cardiomyocyte-
speciﬁc deletion of ERK2 (ERK2cko) using the Cre-LoxP system. ERK2cko
mice were fertile, viable and visibly normal suggesting that the
cardiomyocyte-speciﬁc deletion of ERK2 in ventricles alone did not af-
fect heart development (data not shown). The mRNA levels of ERK2
were signiﬁcantly reduced (73.34%) in ERK2cko ventricles, whereasmRNA levels in skeletal muscle (SM), brain, or liver were indistinguish-
able in comparison to the control group (MLC2v-Cre transgenic mice or
ERK2f/f mice) (Fig. 1A). Protein level of ERK2 in the ventricle was re-
duced by 75.14% in ERK2cko. Comparable protein levels of ERK2 were
found in brain, liver and SM in MLC2v-Cre mice, ERK2f/f or ERK2cko
mice (Fig. 1B). Protein expression or phosphorylation of ERK1 or
MEK1/2 was unchanged in ventricles in all mouse lines (Fig. 1C),
which indicated that ERK2 expression was not affected by Cre expres-
sion or compensatory change of ERK1. In addition, the absence of
ERK2 in the ventricles did not induce alterations by other pathways as
the protein expression of ERK5, p38 and JNK were not different
(Fig. 1C). To further determine whether ERK1 is compensating for the
loss of ERK2, we examined the kinase activity of ERK1/2 in response to
hypertrophic stimulation (Fig. 1D).3.2. ERK2cko mice had an attenuated hypertrophic response to pressure
overload
To determine whether ERK2 is essential for the development of
pressure overload-induced cardiac hypertrophy, 1 or 2 weeks of TAC
was performed on ERK2f/f and ERK2ckomice. Under the similar pressure
gradients (35–40 mm Hg), whilst ERK2f/f mice showed a 30% and 53%
increase in heart weight/tibia length (HW/TL) ratio following 1w- or
2w-TAC, respectively, the increase in ERK2cko mice was signiﬁcantly
lower (only 11% or 33% respectively) (Fig. 2A). Consistent with these
results, the cardiomyocyte cross-sectional area was smaller in ERK2cko
1w-TAC cardiomyocytes (258.91 ± 3.27 μm2) in comparison to ERK2f/f
cardiomyocytess (298.80 ± 2.33 μm2) (Fig. 2B); furthermore; ERK2cko
cardiomyocyte (267.31 ± 13.87 μm2) also showed smaller cross-
sectional area than ERK2f/f cardiomyocyte (332.81 ± 17.02 μm2) after
2w TAC, suggesting a blunted enlargement of cardiomyocyte hypertro-
phy in ERK2cko mice subjected short-term TAC.
Besides hypertrophic growth, pressure overload also induces accu-
mulation of interstitial ﬁbrosis. However, Masson's trichrome staining
showed 62% less ventricular ﬁbrosis in ERK2cko 1w-TACmice compared
to the ERK2f/f 1w-TAC group, while ERK2cko had 33% less ﬁbrosis than
ERK2f/f after 2w-TAC (Fig. 2C).We also investigated apoptosis post pres-
sure overload using TUNEL staining. After 1 or 2 weeks of TAC, 38% or
50% pronounced TUNEL-positive nuclei in ERK2cko ventricles were de-
tected compared to the control-TAC group (Fig. 2D), indicating that
ERK2 was required for cardiomyocyte survival in response to TAC. Con-
sistent with cardiomyocyte growth by H&E staining, echocardiography
substantiated reduced end-diastolic left ventricular posteriorwall thick-
ness (dPW) in ERK2cko compared to ERK2f/f heart subjected to 1w- or
2w-TAC. However, ERK2cko showed decreased FS (33.1 ± 2.5% versus
45.7 ± 4.2% [ERK2f/f]) following 2 weeks of TAC (Fig. 2E).
In concordancewith the above, upregulation of the transcripts of hy-
pertrophic gene markers, atrial natriuretic peptide (ANP) and brain na-
triuretic peptide (BNP), was remarkably blunted in ERK2cko TAC mice
(Fig. 3). We also found that the ﬁbrosis marker genes procollagen type
1α2 (Col1a2), procollagen type 3α3 (Col3a3) and connective tissue
growth factor (Ctgf) were signiﬁcantly less upregulated in ERK2cko ven-
tricles compared to the controls (Fig. 3), suggesting that ERK2cko mice
developed less interstitial ﬁbrosis.
To further investigate the mechanisms involved in the attenuated
hypertrophic response, we examined the activation and expression of
both anti- and pro-hypertrophic signaling pathways including ERK2,
ERK1, MEK1/2, PKB, p38, JNK1/2 and ERK5 following 1 week of TAC
stimulation. Notably, normal heart subjected to TAC showed activation
of ERK2. ERK1 was not able to induce compensatory changes in
ERK2cko-TAC ventricles (Fig. 4). In addition, the activation of the other
hypertrophic regulators was also comparable between the two geno-
types. Taken together, these results suggested that the blunted hyper-
trophic response to pressure overload was due to the absence of ERK2
from the ventricles.
110 S. Ulm et al. / Journal of Molecular and Cellular Cardiology 72 (2014) 104–1163.3. ERK2cko mice were susceptible to heart failure in response to prolonged
TAC
To investigate whether loss of ERK2 in cardiomyocytes predisposes
mice to heart failure, the duration of pressure overload in both geno-
types was extended. After 5 weeks of TAC treatment, ERK2cko and
ERK2f/f mice showed comparably elevated HW/TL ratios (Fig. 5A). Nev-
ertheless, cardiomyocyte cross-sectional area showed a decrease in
ERK2cko compared to ERK2f/f (Fig. 5B). The greater lung weight/tibia
length (LW/TL) ratio observed in ERK2cko 5w-TAC mice indicated pul-
monary edema, likely due to contractile insufﬁciently (Fig. 5C). Under
prolonged hypertrophic stress, both ERK2f/f and the ERK2cko groups
had an increase in ﬁbrosis (Fig. 5D). Expression levels of ANP and BNP
were remarkably increased following 5 weeks of TAC in both ERK2f/f
and ERK2cko mice (Fig. 5E).
Whilst, same as displayed in 1w-TAC heart, the long-term pressure
overload also led to enhanced apoptosis in ERK2cko cardiomyocytes
(14/1 × 104 cells) in comparison to the control group (6.5/1 × 104
cells) (Fig. 5F),which indicated that the increased ventricularwall stress0
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Fig. 5. ERK2cko mice were prone to heart failure after prolonged pressure overload. (A) After 5
sham operated groups. (B) The measurement of mean cross-sectional area showed blunted ER
length (LW/TL) ratio. (D) Quantiﬁcation of interstitial ventricular ﬁbrosis in ERK2f/f and ERK
independent experiments performed in triplicate and normalized to GAPDH content. (F) Aug
(arrows indicate TUNEL positive nuclei, scale = 100 μm). Triple staining was performed: T
and ERK2cko mice following sham or TAC revealed detrimental cardiac dysfunction in ERK2
shown. n= 9 to 10. n.s.: no signiﬁcant difference. Data presented as means ± SEM.due to the lack of appropriate hypertrophy in ERK2cko inducedmore cell
death. Echocardiography revealed that the end-diastolic left ventricular
posterior wall thickness (dPW) was reduced in the ERK2cko heart after
5 weeks of TAC (0.9 ± 0.12 mm versus 1.57 ± 0.20 mm in ERK2f/f
mice), while left ventricular end-diastolic dimension (LVEDD) was
increased (Fig. 5G). This structural change was accompanied by cardiac
dysfunction in ERK2cko mice, in which a substantially reduced FS was
observed (28.62 ± 1.99%) versus ERK2f/f controls (45.68 ± 2.8%)
(Fig. 5G). Collectively, these data demonstrated that, following
5 weeks of TAC, lack of ERK2 led to increased interstitial ﬁbrosis and ap-
optosis. ERK2cko mice were more vulnerable to long-term pressure
overload-induced stress and showed early signs of heart failure.
3.4. Blunted cardiac hypertrophic response was shown in ERK2cko mice
subjected to chronic β-adrenergic stimulation
We next explored whether ERK2 is required for the hypertrophic
cardiac response to chronic β-adrenergic stimulation. After 1 week of
ISO administration (10 mg/kg/day), ERK2 was activated in the normal5w-TACsham
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were analysed by morphological and biochemical studies. After 1 or
3 weeks of ISO, HW/TL ratio was 17% or 15% less in ERK2cko than that in
ERK2f/f respectively (Fig. 6B). Histology performed to investigate
hypertrophic growth at the cellular level indicated that the cardiomyo-
cyte cross-sectional area in ERK2cko 1w-ISO treated mice (264.75 ±
2.80 μm2) was less than the ERK2f/f 1w-ISO group (300.71 ± 4.92 μm2)(Fig. 6C). In addition, 3 weeks of ISO also induced a blunted cross-
sectional area in ERK2cko (287.12 ± 10.8 versus 322.12 ± 8.1 in ERK2f/f)
(Fig. 6C); nevertheless, FS was decreased in ERK2cko followed by 3 week
of ISO stimulation (Fig. 6D). In line with the above results, the transcript
levels of the hypertrophic markers ANP and BNP were lower in ERK2cko
1w-ISO treated mice than in ERK2f/f 1w-ISO ventricles (Fig. 6E). After
long-term stimulation of ISO, ERK2cko displayed augmented apoptosis
112 S. Ulm et al. / Journal of Molecular and Cellular Cardiology 72 (2014) 104–116(Fig. 6F). To summarize, these results indicated that ERK2 is required for
hypertrophic remodeling also caused by chronic β-adrenergic stimula-
tion; furthermore, loss of ERK2 led to increased susceptibility to heart fail-
ure by long-term ISO stimulation.
3.5. ERK2 regulates hypertrophy by nuclear induction of ANP expression
and antagonizes apoptosis
Next, we investigated themolecularmechanism bywhich ERK2 reg-
ulates cardiac hypertrophy by performing in vitro studies in NRCMs. To
diminish expression of ERK2, NRCMs were transfected with rat ERK2
siRNA.Western blot result showed that expression of ERK2was 78% de-
creased by ERK2 siRNA, while ERK1 expression was not changed
(Fig. 7A). NRCMs transfected with either control siRNA or ERK2 siRNA
were subsequently treatedwith PE (30mM) for 48 h. ERK2 siRNA treat-
ed NRCMs did not undergo a hypertrophic growth, whereas NRCMs
transfected with control siRNA showed a remarkable increase in cellA
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ther assessed. Firstly, loss of ERK2 abrogated the hypertrophic effect of
PE, showing reduced ANP expression in NRCMs (Fig. 7C). Next, a lucifer-
ase reporter assay was used to detect the BNP reporter activity. In re-
sponse to PE stress, adenoviral infection of the BNP-luciferase reporter
(Ad-BNP-Luc) in control NRCMs led to enhanced BNP reporter activity.
However, knockdown of ERK2 showed less increase in BNP activity
(Fig. 7D). The results strongly suggested an important role for ERK2 as
an activator of ANP and BNP expression in hypertrophic growth.
In addition, we examined the role of ERK2 in apoptosis with a pro-
apoptotic agent, hydrogen peroxide (H2O2, 100 μM). Following 8 h of
H2O2 treatment, NRCMs transfected with ERK2 siRNA showedmore ob-
vious apoptosis (the number of TUNEL-positive nuclei was 2 times of
that in control NRCMs) (Fig. 7E), along with an augmented level of the
active caspase 3 (Fig. 7F). Taken together, ERK2was required for cardiac
hypertrophic growth in NRCMs in response to PE stimulation, and loss
of ERK2 led to a dramatic increase in apoptotic cardiomyocytes.1w-ISO 3w-ISO
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hypertrophy in response to swimming exercise
Finally, the role of ERK2 in physiological hypertrophy was deter-
mined. To induce physiological hypertrophy, both genotypes were
subjected to swimming exercise for 4 weeks. Histological analysis
demonstrated comparable hypertrophic growth with increased myo-
cardial cross-sectional areas in both swimming groups (Supplement
Fig. IA, B). In addition, increased expression levels of pathological hyper-
trophic markers (ANP, BNP) were not observed (Supplement Fig. IC).
Echocardiographic assessment demonstrated a similarly preserved car-
diac function in both genotypes (Supplement Table I). To estimate
whether ERK2 is involved in the regulation of physiological hypertro-
phy, we examined the activation of ERK2 and found that ERK2 was
not activated in normal heart after long-term swimming (Supplement
Fig. ID). Taken together, swimming induced hypertrophic growth; how-
ever, ERK2was unlikely to be involved in the regulation of physiological
hypertrophy.
4. Discussion
In response to pathological stress, the heart undergoes compensato-
ry hypertrophic enlargement characterized by the increased crosssectional area of individual cardiomyocytes. With prolonged hypertro-
phy, loss of myocytes by apoptosis and interstitial ﬁbrosis lead to
heart failure. In the current study, the speciﬁc biological role of ERK2
in the heart was investigated by using the ERK2 cardiomyocyte-
speciﬁc knockoutmousemodel. In the absence of ERK2, the heart exhib-
ited attenuated cardiac hypertrophic remodeling with short-term pres-
sure overload or chronic β-adrenergic stimulation. However, when
exposed to prolonged pathological stimulation, the mice with cardio-
myocyte speciﬁc deletion of ERK2 were susceptible to heart failure.
4.1. ERK2 is required for pathological hypertrophic growth in response to
overload stress
Themajority of the previous studies to discover the role of ERK1/2 in
myocytes have been performed on several genetically modiﬁed mouse
models. Transgenicmice overexpressingMEK1 or dual-speciﬁcity phos-
phatase 6 (DUSP6) knockouts increased the basal phosphorylation of
ERK1/2, indicating a crucial role of ERK1/2 in developing cardiac hyper-
trophy [18,19]. However, reduction of ERK1 (ERK1−/−) or ERK2
(ERK2+/−) expression or complete inhibition of ERK1/2 by overexpres-
sion of DUSP6 revealed no reduction in pathologic stimulus (TAC)-in-
duced heart hypertrophy [21], indicating that ERK1/2 may not be
necessary for cardiac hypertrophy. A recent study also revealed that
114 S. Ulm et al. / Journal of Molecular and Cellular Cardiology 72 (2014) 104–116the ERK1−/− ERK2cko mice, which contained a deletion of both ERK1
and ERK2, led to generation of spontaneous cardiac hypertrophy with-
out external stimuli and augmented eccentric hypertrophy after
2 weeks of TAC [28].
On the contrary, Sbroggio et al. showed that the absence of IQmotif-
containing GTPase-activating protein 1 (IQGAP1), as a scaffold for the
ERK1/2 cascade, resulted in impaired cardiomyocyte hypertrophy ac-
companied by the blunted reactivation of the gene programme through
diminishing the activity of ERK1/2 [29]. Further evidence indicated that
transgenic mice with enhanced ERK2 Thr188 autophosphorylation
displayed increased hypertrophic growth whereas mice with sup-
pressed ERK2 Thr188 phosphorylation showed resistance to pressure
overload-induced hypertrophy [30]. Therefore, the role of ERK1 or
ERK2 in the heart needed to be speciﬁed. We established the mouse
line with speciﬁc absence of ERK2 but normal expression of ERK1 in
cardiomyocytes which did not show abnormal cardiac development.
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Together, it is plausible to propose that ERK2 activation driven by auto-
phosphorylation may play a more direct role in regulating cardiac
hypertrophy.
Exercise-induced cardiac hypertrophy is a prototype of physiological
heart growth, characterized by normal cardiac structure and preserved
or improved cardiac function. Several lines of evidence have demon-
strated that IGF-PI3K-AKT signaling pathway plays a central role in the
development of physiological in response to exercise [31,32]. In addi-
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115S. Ulm et al. / Journal of Molecular and Cellular Cardiology 72 (2014) 104–116growth and proliferation [33,34]. The potential ability of cardiomyocyte
proliferation is known to serve as a protective basis for pathological car-
diac remodeling [35]. The negative regulation of C/EBPβ byAKT [33] and
cross-talk of AKT-mTOR-p70S6K with Raf-MEK-ERK in cells [36] led us
to investigatewhether ERK2 has function inmediatingphysiological hy-
pertrophy. Surprisingly, in the current study, EKR2cko mice displayed
comparable heart growth by morphological studies after 4 weeks of
swimming exercise. Although ERK1/2 was reported to modulate prolif-
eration via ribosomal s6 kinase (RSK) or transcriptional factors such as
Elk1, c-Fos, and Sp1 in other cells [37], further studies are required to
clarify the molecular mechanism of how ERK2 is involved in regulation
of cardiomyocyte proliferation.
4.2. EKR2 is an anti-apoptotic factor in the cardiomyocytes
We also examined the role of ERK2 in regulating cardiomyocyte sur-
vival. The present study demonstrated the cardiomyocyte protective
function of ERK2. A previous study reported that pro-apoptotic genes,
such as Bad and p53, were upregulated in the absence of ERK1/2 [30],
suggesting that ERK1/2 suppressed apoptotic response within the
heart. Consistently, the current study detected enhanced caspase 3 ac-
tivity in ERK2 knocked down NRCMs following stimulation by H2O2.
Caspase 3 is known to interact with caspase 9 which were demonstrat-
ed to be inhibited by activation of the ERK pathway [38]. Several con-
vincing evidence indicated that ERK1/2 has anti-apoptotic function in
cells due to inactivation of pro-apoptotic factors, e.g. Bimand BAD, to in-
hibit the release of caspase members; in the meantime, they can acti-
vate pro-survival factors, e.g. Bcl-Xl and CREB [39]. However, ERK1
and ERK2 have distinct target factors of cell death and survival, for in-
stance, ERK2 was shown not only to dominantly inactivate the pro-
apoptotic gene Noxa and p53 upregulated modulator of apoptosis
(PUMA) but also efﬁciently repress caspase 8 and cleaved poly ADP ri-
bose polymerase (PARP) inmelanoma cells [40]. Although further stud-
ies are required to uncover speciﬁc downstream targets of ERK2 inprotecting cardiomyocytes following stress, ERK2 seems to be necessary
for maintaining cardiac function during hypertrophic remodeling
and for protecting cardiomyocytes against pathologic stress-induced
apoptosis.
4.3. The role of ERK2 in regulating the formation of interstitial ﬁbrosis
awaits determination
Accumulation of interstitial ﬁbrosis is also a key mediator for heart
function. The present study showed less ﬁbrosis in ERK2ckomice follow-
ing short-term TAC, determined by histological staining and decreased
expression of the ﬁbrotic gene markers. CTGF, as a key mediator of car-
diac ﬁbrosis, can be expressed and secreted from cardiomyocytes to in-
duce ﬁbrosis in response to stimulation [41]. Previous studies
determined the regulation of CTGF expression by transcriptional factor
MEF2 or STAT3 in ﬁbroblasts [42,43]. Thus, less interstitial ﬁbrosis and
CtgfmRNA in ERK2cko 1w- or 2w-TAC hearts are likely due to downreg-
ulation of MEF2 or STAT3.
However, following prolonged pathological stress-induced cardiac
dysfunction, comparable ﬁbrosis formation was detected in ERK2cko
5w-TAC hearts compared with the ERK2f/f group. It is plausible that
ERK2 knockout cardiomyocytes are sensitized to stress-induced cell
death and sequentially beget heart dysfunction, in which ﬁbroblasts are
activated to generatemoreﬁbrosis. In addition, Thumet al. demonstrated
that, in cardiac ﬁbroblasts, micro RNA-21 promoted cardiac ﬁbrosis by
promoting ERK1/2 signaling following long-term pressure overload
[44]. Nevertheless, future studies are required to speciﬁcally focus on
the role of ERK2 in cardiac ﬁbrosis formation during pathological hyper-
trophy by using mice with cardiac ﬁbroblast-speciﬁc deletion of ERK2.
5. Conclusion
In conclusion, this study provides convincing evidence that clariﬁes
the in vivo role of ERK2 in the heart. ERK2 is required for adaptive
116 S. Ulm et al. / Journal of Molecular and Cellular Cardiology 72 (2014) 104–116hypertrophic remodeling and protection of cardiomyocytes in response
to pathological. However, ERK2 is not involved in physiologic cardiac
growth, which contributes the invaluable information for the develop-
ment of new therapeutic strategies treating heart diseases.
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